DK3092491T3 - Proteiner, som er målrettede orthologer - Google Patents

Proteiner, som er målrettede orthologer Download PDF

Info

Publication number
DK3092491T3
DK3092491T3 DK15734951.5T DK15734951T DK3092491T3 DK 3092491 T3 DK3092491 T3 DK 3092491T3 DK 15734951 T DK15734951 T DK 15734951T DK 3092491 T3 DK3092491 T3 DK 3092491T3
Authority
DK
Denmark
Prior art keywords
sequence
antibody
species
protein
cells
Prior art date
Application number
DK15734951.5T
Other languages
English (en)
Inventor
Jay Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Application granted granted Critical
Publication of DK3092491T3 publication Critical patent/DK3092491T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Claims (15)

1. Fremgangsmåde til identifikation af et flere arter omfattende mutant polypeptid ud fra et modelpolypeptid fra en art valgt blandt menneske og ikke-menneske-dyr, hvor modelpolypeptidet udviser en aktivitet på et mål fra arten og har totalt n aminosyrerester, hvilken fremgangsmåde omfatter følgende trin: i. generering af et bibliotek af mutante polypeptider i en eukaryotisk cellevært ud fra modelpolypeptidet ved at generere n-1 separate sæt af mutante polypeptider ud fra modelpolypeptidet, idet hvert sæt omfatter mutante polypeptider med X forskellige forudbestemte aminosyrerester ved en enkelt forudbestemt position i modelpolypeptidet, idet hvert sæt af mutante polypeptider afviger i den enkelte forudbestemte position, og et antal forskellige mutante polypeptider genereret er ækvivalent med [n-1] x X; ii. udvælgelse af mutante polypeptider fra biblioteket af mutante polypeptider i den eukaryotiske cellevært, som udviser aktiviteten på en ortholog af målet i en anden art valgt blandt menneske og ikke-menneske-dyr; og iii. screening af de valgte mutante polypeptider i den eukaryotiske cellevært for et flere arter omfattende mutant polypeptid, som udviser aktiviteten på målet.
2. Fremgangsmåde ifølge krav 1, hvor modelpolypeptidet er et antistof og målet er et antigen, som antistoffet specifikt binder til.
3. Fremgangsmåde ifølge krav 1, hvor modelpolypeptidet er et enzym og målet er et substrat af enzymet.
4. Fremgangsmåde ifølge krav 1, hvor modelpolypeptidet er et hormon og målet er en receptor for hormonet.
5. Fremgangsmåde ifølge krav 1, hvor genereringstrinnet omfatter anvendelse af comprehensive positional evolution (CPE).
6. Fremgangsmåde ifølge krav 1, hvor n er 19 og det totale antal af forskellige polypeptider, som genereres, er ækvivalent med [n-1] x 19.
7. Fremgangsmåde ifølge krav 1, hvor hvert sæt af de mutante polypeptider genereres ved: inkorporering af Ν,Ν,Ν ved en forudbestemt codonposition i et polynukleotid, som koder for modelpolypeptidet.
8. Fremgangsmåde ifølge krav 1, hvor arten er menneske.
9. Fremgangsmåde ifølge krav 8, hvor den anden art er valgt blandt rotte, mus, kanin, hamster, marsvin, abe, hund, kat og ikke-menneske-primater.
10. Fremgangsmåde ifølge krav 1, hvor arten og den anden art er forskellige og uafhængigt valgt blandt rotte, mus, kanin, hamster, marsvin, abe, hund, kat og ikke-menneske-primater.
11. Fremgangsmåde ifølge krav 1, hvor den eukaryotiske cellevært er valgt blandt en gærcellevært og en mammal cellevært.
12. Fremgangsmåde ifølge krav 11, hvor den eukaryotiske cellevært er den mammale cellevært.
13. Fremgangsmåde ifølge krav 12, hvor den mammale cellevært er valgt blandt CHO, HEK293, IM9, DS-1, THP-1, Hep G2, COS, NIH 3T3, C33a, A549, A375, SK-MEL-28, DU 145, PC-3, HCT 116, Mia PACA-2, ACHN, Jurkat, MM1, Ovcar 3, HT 1080, Panc-1, U266, 769P, BT-474, Caco-2, HCC 1954, MDA-MB-468, LnCAP, NRK-49F, SP2/0 cellelinier, musesplenocyter og kanin PBMC.
14. Fremgangsmåde ifølge krav 11, hvor den eukaryotiske cellevært er gærcelleværten.
15. Fremgangsmåde ifølge krav 14, hvor gærcelleværten er valgt blandt S. cerevisiae og en art af Pichia.
DK15734951.5T 2014-01-07 2015-01-07 Proteiner, som er målrettede orthologer DK3092491T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461924487P 2014-01-07 2014-01-07
PCT/US2015/010498 WO2015105888A1 (en) 2014-01-07 2015-01-07 Proteins targeting orthologs

Publications (1)

Publication Number Publication Date
DK3092491T3 true DK3092491T3 (da) 2019-02-11

Family

ID=53524311

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15734951.5T DK3092491T3 (da) 2014-01-07 2015-01-07 Proteiner, som er målrettede orthologer
DK18196116.0T DK3447493T3 (da) 2014-01-07 2015-01-07 Proteinrettede ortologer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18196116.0T DK3447493T3 (da) 2014-01-07 2015-01-07 Proteinrettede ortologer

Country Status (9)

Country Link
US (2) US11293929B2 (da)
EP (2) EP3447493B1 (da)
CN (2) CN105849564B (da)
AU (2) AU2015204840B2 (da)
CA (1) CA2935577C (da)
DK (2) DK3092491T3 (da)
ES (2) ES2709388T3 (da)
SG (1) SG10201806532RA (da)
WO (1) WO2015105888A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220414855A1 (en) * 2021-06-25 2022-12-29 Fei Company Area selection in charged particle microscope imaging

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957858A (en) 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
AU624601B2 (en) 1988-01-21 1992-06-18 Genentech Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
EP0365627B1 (en) 1988-03-24 1993-12-22 University Of Iowa Research Foundation Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69333243T2 (de) 1992-11-24 2004-08-19 G.D. Searle & Co., Chicago Mutierte polypeptide des interleukin-3(il-3)
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
RU2363707C2 (ru) 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
US8843356B2 (en) * 2002-12-27 2014-09-23 Merck Sharp & Dohme Corp. Computer systems and methods for associating genes with traits using cross species data
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
LT2520590T (lt) * 2007-04-03 2018-09-10 Amgen Research (Munich) Gmbh Susijusioms rūšims specifinis rišantis domenas
MX2009010611A (es) * 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
EP2153844A1 (en) 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
US9260522B2 (en) * 2008-10-01 2016-02-16 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
ES2652340T3 (es) 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
CA2804746C (en) * 2010-07-16 2022-01-11 Jay M. Short Novel methods of protein evolution
WO2012092376A2 (en) 2010-12-31 2012-07-05 Short Jay M Comprehensive monoclonal antibody generation

Also Published As

Publication number Publication date
EP3092491A1 (en) 2016-11-16
EP3092491A4 (en) 2017-03-29
AU2020202783B2 (en) 2022-08-25
AU2015204840B2 (en) 2020-01-30
CN105849564A (zh) 2016-08-10
CA2935577A1 (en) 2015-07-16
EP3447493A1 (en) 2019-02-27
AU2015204840A1 (en) 2016-05-19
WO2015105888A1 (en) 2015-07-16
US20180259536A1 (en) 2018-09-13
EP3447493B1 (en) 2020-05-13
US11293929B2 (en) 2022-04-05
US20220341941A1 (en) 2022-10-27
CN105849564B (zh) 2021-06-25
CA2935577C (en) 2023-04-04
ES2709388T3 (es) 2019-04-16
EP3092491B1 (en) 2018-10-31
SG10201806532RA (en) 2018-09-27
CN113504375A (zh) 2021-10-15
AU2020202783A1 (en) 2020-05-14
CN113504375B (zh) 2024-01-09
DK3447493T3 (da) 2020-08-17
ES2819865T3 (es) 2021-04-19

Similar Documents

Publication Publication Date Title
US11639365B2 (en) Methods of protein evolution
US10047357B2 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
US20220341941A1 (en) Proteins targeting orthologs
AU2018226408B2 (en) Novel methods of protein evolution